

Review

Open Access

Chemical markers for the quality control of herbal medicines: an overview

Songlin Li, Quanbin Han, Chunfeng Qiao, Jingzheng Song, Chuen Lung Cheng and Hongxi Xu*

Address: Chinese Medicine Laboratory, Hong Kong Jockey Club Institute of Chinese Medicine, Hong Kong SAR, PR China

Email: Songlin Li - slli@hkjicm.org; Quanbin Han - qbhan@hkjicm.org; Chunfeng Qiao - cfqiao@hkjicm.org; Jingzheng Song - jzsong@hkjicm.org; Chuen Lung Cheng - andrewch@hkjicm.org; Hongxi Xu* - xuhongxi@hkjicm.org

* Corresponding author

Published: 28 June 2008

Chinese Medicine 2008, 3:7 doi:10.1186/1749-8546-3-7

This article is available from: <http://www.cmjournal.org/content/3/1/7>

© 2008 Li et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Received: 8 March 2008

Accepted: 28 June 2008

Abstract

Selection of chemical markers is crucial for the quality control of herbal medicines, including authentication of genuine species, harvesting the best quality raw materials, evaluation of post-harvesting handling, assessment of intermediates and finished products, and detection of harmful or toxic ingredients. Ideal chemical markers should be the therapeutic components of herbal medicines. However, for most herbal medicines, the therapeutic components have not been fully elucidated or easily monitored. Bioactive, characteristic, main, synergistic, correlative, toxic and general components may be selected. This article reviews the effective use of chemical markers in the quality control of herbal medicines including the selection criteria considering the roles and physicochemical factors which may affect the effective use of chemical markers.

Background

Herbal medicines, also known as botanical medicines or phytomedicines, refer to the medicinal products of plant roots, leaves, barks, seeds, berries or flowers that can be used to promote health and treat diseases. Medicinal use of plants has a long history worldwide. According to the World Health Organization (WHO), traditional herbal preparations account for 30–50% of the total medicinal consumption in China [1]. There have always been concerns about the inconsistent composition of herbal medicines and occasional cases of intoxication by adulterants and/or toxic components. Quality control of herbal medicines aims to ensure their consistency, safety and efficacy.

Chemical fingerprinting has been demonstrated to be a powerful technique for the quality control of herbal medicines. A chemical fingerprint is a unique pattern that indi-

cates the presence of multiple chemical markers within a sample.

The European Medicines Agency (EMEA) defines chemical markers as chemically defined constituents or groups of constituents of a herbal medicinal product which are of interest for quality control purposes regardless whether they possess any therapeutic activity [2]. Ideally, chemical markers should be unique components that contribute to the therapeutic effects of a herbal medicine. As only a small number of chemical compounds were shown to have clear pharmacological actions, other chemical components are also used as markers. The quantity of a chemical marker can be an indicator of the quality of a herbal medicine.

The overall quality of a herbal medicine may be affected by many factors, including seasonal changes, harvesting time, cultivation sites, post-harvesting processing, adulterants or substitutes of raw materials, and procedures in extraction and preparation. From harvesting to manufacturing, chemical markers play a crucial role in evaluating the quality of herbal medicines. Moreover, the study of chemical markers is applicable to many research areas, including authentication of genuine species, search for new resources or substitutes of raw materials, optimization of extraction and purification methods, structure elucidation and purity determination. Systematic investigations using chemical markers may lead to discoveries and development of new drugs.

In this review, we summarise selection criteria for chemical markers and how chemical markers are used to evaluate the quality of herbal medicines.

Selection of chemical markers

A total of 282 chemical markers are listed in the Chinese Pharmacopoeia (2005 edition) for the quality control of Chinese herbal medicines [3]. As discussed in the monographs of the American Herbal Pharmacopoeia (AHP), the use of single or multiple chemical markers was important to quality control [4]. Scientists and regulatory agencies have paid attention to the selection of chemical markers in quality control. The EMEA categorises chemical markers into analytical markers and active markers [2]. According to the definition by the EMEA, analytical markers are the constituents or groups of constituents that serve solely for analytical purposes, whereas active markers are the constituents or groups of constituents that contribute to therapeutic activities. There are other classifications of chemical markers. For example, Srinivasan proposed the following four categories: active principles, active markers, analytical markers and negative markers [5]. Active principles possess known clinical activities; active markers contribute to clinical efficacy; analytical markers have no clinical or pharmacological activities; negative markers demonstrate allergenic or toxic properties. All markers may contribute to the evaluation, standardisation and safety assessment of herbal medicines. Lin *et al.* expanded Srinivasan's classification into seven categories, namely active principles, active markers, group markers, chemical fingerprints, analytical markers, 'phantom' markers and negative markers [6]. Group chemical markers have similar chemical structures and/or physical properties. The pharmacological activities of individual components are not necessarily known. Polysaccharides are classified under this category. This type of markers is not necessarily specific and can be easily masked by other components especially in proprietary products. 'Phantom' markers are constituents that have known pharmacological activities; however, they can be undetectable in some herbal medi-

cines due to low quantities. Special care should be taken when 'phantom' markers were selected as chemical markers for quality control [6]. While group chemical markers have a lower resolving power in qualitative analysis, chemical fingerprinting cannot provide adequate quantitative information.

In this paper, we suggest a new classification of eight categories of chemical markers, namely (1) therapeutic components, (2) bioactive components, (3) synergistic components, (4) characteristic components, (5) main components, (6) correlative components, (7) toxic components, and (8) general components used with fingerprint spectrum. These eight categories are defined and discussed in the subsequent sections.

Therapeutic components

Therapeutic components possess direct therapeutic effects of a herbal medicine. They may be used as chemical markers for both qualitative and quantitative assessments.

Originated from the bulbs of *Fritillaria* species (family Liliaceae), *Bulbus Fritillariae* (*Beimu*) is commonly prescribed as an antitussive and expectorant in Chinese medicine practice. Five different *Bulbus Fritillariae* derived from nine *Fritillaria* species are documented in the Chinese Pharmacopoeia [3]. Isosteroidal alkaloids of *Bulbus Fritillariae*, including verticine, verticinone and imperialine, were identified as the major therapeutic components that account for the antitussive effect [7–9]. Therefore, isosteroidal alkaloids were selected as the chemical markers for the quality assessment of *Bulbus Fritillariae* using a series of chromatographic techniques such as pre-column derivatizing gas chromatography – flame ionization detection (GC-FID), direct GC-FID, gas chromatography – mass spectrometry (GC-MS), pre-column derivatizing high-performance liquid chromatography – ultraviolet detection (HPLC-UV), high-performance liquid chromatography – evaporative light scattering detection (HPLC-ELSD) and high-performance liquid chromatography – mass spectrometry (HPLC-MS) methods [10].

Artemisinin from *Herba Artemisiae Annuae* (*Qinghao*) is another example of therapeutic component. *Herba Artemisiae Annuae* is well known for its potent anti-malarial activity [11]. Artemisinin inhibits *Plasmodium falciparum* and *Plasmodium vivax*, two pathogens that cause malaria [12,13]. Artemisinin is now used as a chemical marker in HPLC-ELSD [14], GC-FID [15] and GC-MS [15,16] for assessing the quality of the plant (parts and whole) at various stages [15], including the green and dead leaves of the plant [16].

Bioactive components

Bioactive components are structurally different chemicals within a herbal medicine; while individual components may not have direct therapeutic effects, the combination of their bioactivities does contribute to the therapeutic effects. Bioactive components may be used as chemical markers for qualitative and quantitative assessment.

According to Chinese medicine theories, *Radix Astragali* (*Huangqi*), derived from the roots of *Astragalus membranaceus* (Fisch.) Bge. or *A. membranaceus* var. *mongholicus* (Bge.) Hsiao, is used to reinforce *qi*. Isoflavonoids, saponins and polysaccharides of *Radix Astragali* showed pharmacological actions in immune and circulatory systems, which were consistent with the Chinese medicine indications [17]. These bioactive components, including isoflavonoids and saponins, were used simultaneously in the evaluation of the quality of *Radix Astragali* [18-20].

Synergistic components

Synergistic components do not contribute to the therapeutic effects or related bioactivities directly. However, they act synergistically to reinforce the bioactivities of other components, thereby modulating the therapeutic effects of the herbal medicine. Synergistic components may be used as chemical markers for qualitative and quantitative assessment.

The products of St John's wort (*Hypericum perforatum* L.) are popular for treating mild depression [21]. Butterweck *et al.* reviewed the research progress on the phytochemistry and pharmacology of St John's wort [22,23]. Naphthodianthrone, hypericin, and hyperforin (a phloroglucinol derivative) were identified as the major components that contribute to the pharmacological activities of St John's wort. Rutin, a ubiquitous flavonoid of natural products, demonstrated synergistic antidepressant actions in St John's wort [24]. In a forced swimming test on rats, extracts of St John's wort with various chemical profiles were tested, among which the extract containing about 3% of rutin showed positive effects, whereas the extracts containing less than 3% of rutin were inactive. The extracts became active when the level of rutin was increased to about 3%. However, rutin alone did not show any effects under the same conditions [24]. These results suggest that chemicals in St John's wort work synergistically to achieve the antidepressant effects. Therefore, naphthodianthrones, phloroglucinols and flavonoids may be used as chemical markers for the quality control of St John's wort [25-29].

Characteristic components

While characteristic components may contribute to the therapeutic effects, they must be specific and/or unique ingredients of a herbal medicine.

Terpene lactones in the leaves of *Ginkgo biloba* L. (*Yinxing*) exemplify characteristic components. EGb 761, a standardised leave extract of *Ginkgo biloba* is a well defined product for the treatment of cardiovascular diseases, memory loss and cognitive disorders associated with age-related dementia [30]. Flavonoids and terpene lactones are responsible for the medicinal effects of EGb 761 [31]. Flavonoids, terpene lactones including ginkgolides A, B and C, and bilobalide are chemical markers for the quality control of *Ginkgo biloba* leave extracts [31-34]. EGb 761 contains 6% of terpene lactones (2.8–3.4% of ginkgolides A, B and C, and 2.6–3.2% of bilobalide) and 24% of flavone glycosides. Aglycons are primarily quercetin, kaempferol and isorhamnetin.

Valerenic acids, the characteristic components of valerian derived from the roots of *Valeriana officinalis* L., have sedative effects and improve sleep quality [35,36]. Valerenic acids are used as chemical markers to evaluate the quality of valerian preparations although their sedative effects have not been fully elucidated [37]. These chemical markers are also used for studying *in vitro* release of coated and uncoated tablets [38] and stability test for valerian ground materials and extracts [39].

Main components

Main components are the most abundant in a herbal medicine (or significantly more abundant than other components). They are not characteristic components and their bioactivities may not be known. Main components may be used for both qualitative and quantitative analysis of herbal medicines especially for differentiation and stability evaluation.

Four well-known Chinese herbal medicines derived from the genus *Panax*, namely (1) *Radix et Rhizoma Ginseng* (*Renshen*), (2) *Radix et Rhizoma Ginseng Rubra* (*Hongshen*), (3) *Radix Panacis Quinquefolii* (*Xiyangshen*) and (4) *Radix et Rhizoma Notoginseng* (*Sanqi*) [39], contain triterpenoid saponins including ginsenoside Rg1, Re, Rb1 and notoginsenoside R1 as their main components [40-42]. Through qualitative and quantitative comparison of the saponin profiles [43-45], these four herbs can be differentiated from one another [42,46].

Herba Epimedii (*Yinyanghuo*), derived from the aerial parts of *Epimedium brevicornum* Maxim., *E. sagittatum* (Sieb. et Zucc.) Maxim., *E. pubescens* Maxim., *E. wushanense* T. S. Ying or *E. koreanicum* Nakai, has been traditionally used to reinforce kidney-yang (*shenyang*), strengthen tendons and bones, and relieve rheumatic conditions [47]. Flavonoids including epimedin A, B, C and icariin are the main components of *Herba Epimedii* [48]. A 24-month randomised, double-blinded and placebo-controlled clinical study showed that flavonoids from *Herba Epimedii* exerted ben-

eficial effects on preventing osteopenia in late post-menopausal women [49]. According to the Chinese Pharmacopoeia (2005 edition), total flavonoids and icariin are used as chemical markers for *Herba Epimedii* [47]. In a recent study, Chen *et al.* developed an HPLC method to simultaneously quantify up to 15 flavonoids, of which epimedin A, B, C and icariin were selected as chemical markers for the quality assessment of the *Epimedium* species documented in the Chinese Pharmacopoeia (2005 edition) [50].

Correlative components

Correlative components in herbal medicines have close relationship with one another. For example, these components may be the precursors, products or metabolites of a chemical or enzymatic reaction. Correlative components can be used as chemical markers to evaluate the quality of herbal medicines originated from different geographical regions and stored for different periods of time.

According to the Chinese Pharmacopoeia (2005 edition), only psoralen and isopsoralen (Figure 1) are used as chemical markers for assessing the quality of *Fructus Psoraleae* (*Buguzhi*) [51]. Recently, our group identified glycosides, psoralenoside and isopsoralenoside (Figure 1) found them useful as the chemical markers for *Fructus Psoraleae* [52]. The levels of psoralen and isopsoralen are inversely correlated to the level of glycosides psoralenoside and isopsoralenoside [53]. When extracted with 50% methanol, samples had high levels of psoralen and isopsoralen and a minute amount of psoralenoside and isopsoralenoside. When moistened with 100% methanol, dried and extracted with 50% methanol, samples contained all four components. Psoralen and isopsoralen may be the enzymatic reaction products of psoralenoside and isopsoralenoside respectively. After incubation of a psoralenoside and isopsoralenoside solution with β -glucosidase at 36°C for 24 hours, the amount of psoralen and isopsoralen became detected. Psoralenoside and isopsoralenoside, therefore, may be used as chemical markers for the quality control of *Fructus Psoraleae* [53].

soralenoside. When moistened with 100% methanol, dried and extracted with 50% methanol, samples contained all four components. Psoralen and isopsoralen may be the enzymatic reaction products of psoralenoside and isopsoralenoside respectively. After incubation of a psoralenoside and isopsoralenoside solution with β -glucosidase at 36°C for 24 hours, the amount of psoralen and isopsoralen became detected. Psoralenoside and isopsoralenoside, therefore, may be used as chemical markers for the quality control of *Fructus Psoraleae* [53].

Toxic components

Traditional Chinese medicine literature and modern toxicological studies documented some toxic components of medicinal herbs. For instance, aristolochic acids (AAs) and pyrrolizidine alkaloids (PAs) may cause nephrotoxicity and hepatotoxicity respectively [54,55].

The use of three herbal medicines that contain AAs, namely *Radix Aristolochiae Fangchi* (*Guangfangji*), *Caulis Aristolochiae Manshuriensis* (*Guanmutong*) and *Radix Aristolochiae* (*Qingmuxiang*), have been prohibited in China since 2004 [56]. These three herbs were traditionally used to relieve pain and treat arthritis. *Radix et Rhizoma Asari* (*Xixin*) was traditionally sourced from the whole plants of *Asarum heterotropoides* Fr. Schmidt var. *mandshuricum* (maxim.) Kitag., *A. sieboldii* Miq. var. *seoulense* Nakai or *A. sieboldii* Miq. Its medicinal use has now been officially limited to the roots and rhizomes because the roots and rhizomes contain a much lower level of AAs than the aerial parts [57]. AAs are now used as markers to control




Figure 1

Psoralen, isopsoralen, psoralenoside, isopsoralenoside and their correlation in *Psoralea corylifolia* L.

nephrotoxic herbs and proprietary herbal products [58-61].

There are over 6,000 plant species containing PAs which can cause hepatic veno-occlusive disease [62]. There have been various PA restriction guidelines issued by government bodies and organisations. According to the WHO guidelines issued in 1989, the lowest intake rate of toxic PAs that may cause veno-occlusive disease in human is 15 µg/kg/day [63]. In 1993, the American Herbal Products Association (AHPA) alerted its members to restrict the use of comfrey, a herbal medicine that contains PAs for external applications. In 2001, the Food and Drug Administration (FDA) of the United States recalled comfrey from all dietary supplements [64]. In 2007, the Medicines and Healthcare Products Regulatory Agency (MHRA) of the United Kingdom advised all herbal interest groups to withdraw all unlicensed proprietary products that may contain hepatotoxic PAs from *Senecio* species [65]. PAs are thus markers for detection of hepatotoxic components in herbs [66-72].

General components coupled with 'fingerprints'

General components are common and specific components present in a particular species, genus or family. These components may be used with 'fingerprints' for quality control purposes.

Lobetyolin, a polyacetylene compound, is used as a marker for *Radix Codonopsis* (*Dangshen*) in thin-layer chromatography (TLC). *Radix Codonopsis* is derived from the roots of three *Codonopsis* species, namely *Codonopsis pilosula* (Franch.) Nannf., *C. pilosula* Nannf. var. *modesta* (Nannf.) L. T. Shen or *C. tangshen* Oliv. [73]. Our study showed that other five *Codonopsis* species that are common substitutes of *Radix Codonopsis* also contain lobetyolin. They are *C. tubulosa* Kom., *C. subglobosa* W. W. Smith, *C. clematidea* (Schyneek) C. B. Cl., *C. canescens* Nannf. and *C. lanceolata* (Sieb. et Zucc.) Trautv. Moreover, the roots of *Campanumoea javanica* Bl. and *Platycodon grandiflorum* (Jacq.) A. DC. (family Campanulaceae), which are easily

confused with *Radix Codonopsis*, also contained lobetyolin. Therefore, lobetyolin may be used as a general chemical marker coupled with HPLC-UV 'fingerprints' to differentiate *Radix Codonopsis* from its substitutes and adulterants [74].

As a chemical component may have more than one attribute, a component may belong to multiple categories. For example, ginkgolides A, B and C, and bilobalide are not only characteristic components, but also bioactive components of *Ginkgo biloba*. Ginsenoside Rg1, Re and Rb1 are both main and bioactive components of *Panax ginseng*. Categories of chemical markers are summarised in Table 1.

Applications of chemical markers

In this section, we describe cases to exemplify how chemical markers are used to evaluate the quality of herbal medicines in manufacturing, and as potential lead compounds for new drug development.

Identification of adulterants



Derived from the resin of *Garcinia hanburyi* Hook f. (family Guttiferae), gamboges (*Tenghuang*) has been used in China to treat scabies, tinea and malignant boil [75], and in Thailand to treat infected wounds, pain and oedema [76]. Characteristic polyprenylated caged xanthones including gambogic acid, gambogenic acid were isolated as the main and bioactive components of gamboges [77]. In our previous study, an adulterant of gamboges was differentiated from the authentic sample by an HPLC-UV method using eight caged xanthones as chemical markers. The chromatogram of gamboges had all eight compounds, while the adulterant showed none of them (Figure 2).

Differentiation of herbal medicines with multiple sources

Radix Stemonae (*Baibu*) is a traditional antitussive and insecticidal herbal medicine derived from the roots of three *Stemonae* species, namely *Stemona tuberosa* Lour, *S. sessilifolia* (Mig.) Mig. and *S. japonica* Mig. [78]. The Ste-

Table I: Quality control interests and disadvantages of chemical markers

Category	Quality control interests	Disadvantages
Therapeutic components	Indicating efficacy	Not always obtained
Toxic components	Safety assurance	Need extensive toxicological studies
Bioactive components	May indicate efficacy	Not always indicate the overall quality
Main components	Stability and consistency test	Not always indicate the overall quality
Characteristic components	Qualitative identification	Not always obtained
Synergistic components	Revealing synergistic actions of multi-components	Need extensive pharmacological studies
Correlative components	Prediction of storage period, extraction methods and sometimes collection site etc.	Need extensive phytochemical studies
General components used together with fingerprint spectrum	Indicating overall quality when used together with fingerprint spectrum	Mass data analysis

**Figure 2**

HPLC chromatograms of gamboge (A) and its adulterant (B). **1**, Morellie acid; **2**, R-30-hydroxygambogic acid; **3**, S-30-hydroxygambogic acid; **4**, Gambogenic acid; **5**, R-isogambogic acid; **6**, S-isogambogic acid; **7**, R-gambogic acid; **8**, S-gambogic acid.

mona alkaloids were pharmacologically proven to be responsible for the antitussive and insecticidal effects of *Radix Stemona* [79-83]. In our studies, we observed that the chemical profiles of these three *Stemona* species varied greatly. Croomine-type alkaloids such as croomine were detected in all three species, while protostemonine-type alkaloids such as protostemonine and maistemonine were detected in *S. japonica* and *S. sessilifolia*. Moreover, stichoneurine-type alkaloids such as stemoninine, neotuberostemonine and tuberostemonine were only found in *S. tuberosa*. *Stemona* alkaloids may be used as markers to discriminate the three *Stemona* species [84,85].

Determination of the best harvesting time

Rhizoma Chuanxiong (*Chuanxiong*) is one of the traditional Chinese medicinal herbs frequently used to treat cerebro- and cardio-vascular diseases. Various chemical compounds have been isolated and identified from *Rhizoma Chuanxiong*, including ferulic acid, senkyunolide I, senkyunolide H, senkyunolide A, coniferyl ferulate, Z-ligustilide, 3-butylidenephthalide, riligustilide and levistolide A [86-92]. These chemicals have multiple biological activities which may contribute to the therapeutic effects of the herb [93-99]. Thus, major bioactive components senkyunolide A, coniferyl ferulate, Z-ligustilide, ferulic acid, 3-butylidenephthalide, riligustilide and levistolide A may be used as markers to select the best harvesting time. A previous study using these markers suggested that the best harvesting time for *Rhizoma Chuanxiong* is from mid April to late May [100].

Confirmation of collection sites

In our studies on the chemistry and antitussive activities of *Radix Stemona* [101-103], four chemical profiles of *S. tuberosa* of different geographic sources were characterised using croomine, stemoninine, neotuberostemonine or tuberostemonine as markers [102]. Moreover, the total alkaloid of *S. tuberosa* exhibited various levels of antitussive activities in a citric acid-induced guinea pig cough model [82]. Croomine, stemoninine, neotuberostemonine and tuberostemonine all possess significant antitussive activities, however, croomine (croomine type) act on the central nervous system pathway, whereas the other three alkaloids (stichoneurine type) acted on the peripheral pathway of cough reflex [82]. In terms of safety, those containing stichoneurine-type alkaloids are more suitable *Radix Stemona* sources than those containing croomine as the major component. Croomine, stemoninine, neotuberostemonine, and tuberostemonine may be used as markers to confirm the collection sites for *S. tuberosa* (e.g. Shizhu and Erbian in Sichuan province, Masupo and Baoshan in Yunnan province, Shanglin in Guangxi province or Yudu in Jiangxi province, China) which contains higher levels of stemoninine, neotuberostemonine or tuberostemonine, and a low level of croomine [102].

Assessment of processing methods

In general practice, most herbs must be processed to reduce toxicity. For example, *Radix Aconiti* (*Chuanwu*) derived from the root of *Aconitum carmichaeli* Debx [104], is a well known toxic and potent herbal medicine. Cases of intoxication and even death were reported in China and Japan [105-107]. The herb is processed by boiling in water for 4-6 hours or steaming for 6-8 hours [108]. The toxic components of this herb are diester-diterpene *Aconitum* alkaloids, such as aconitine, mesaconitine and hypaconitine. When processed, these alkaloids hydrolyse into their respective analogues collectively known as monoester alkaloids [109]. Monoester alkaloids are much less toxic than diester alkaloids [110]. These six *Aconitum* alkaloids may be used to evaluate *Radix Aconiti* [111].

Quality evaluation of herbal parts

Traditionally, *Radix Astragali* is graded according to its diameter, length and physical appearance. Isoflavonoids and saponins were recognised as the major bioactive components attributed to the therapeutic effects of *Radix Astragali*. These two types of components were used to evaluate the quality of *Radix Astragali* in our study, in which 25 samples of *Radix Astragali* were collected from four cultivating regions in China [112]. The contents of 11 main isoflavonoids and three major astragalosides were analysed. Contrary to the traditional notion, thin roots contained more astragalosides than thick ones. Moreover, the content of astragalosides in the bark were over 74-fold higher than that in the xylem. There was no difference in isoflavonoid content between the thin and thick roots, or the bark and the xylem. These results suggest that the thin root *Radix Astragali* is of better quality [112].

Identification and quantitative determination of proprietary products
Qingfu Guanjie Shu (QGS, also known as JCICM-6) capsule is a proprietary product to treat rheumatoid arthritis. QGS has significant suppressive effects on arthritic [113] and acute inflammation in animal models [114]. The formula of QGS is composed of five anti-inflammatory and anti-arthritis herbs, namely *Caulis Sinomenii*, *Radix Paeoniae Alba*, *Cortex Moutan*, *Rhizoma Curcumae Longae* and *Radix Aconiti Lateralis Preparata*. Sinomenine, paeoniflorin, paeonol, curcumin and hypaconitine are the major constituents of the five herbs respectively, all of which have significant *in vivo* and *in vitro* effects including anti-inflammation, analgesia, anti-arthritis and immunosuppression [115-118]. Thus, HPLC methods were developed with these five chemicals as markers in the manufacturing process of QGS [111,119]. Immediately after production, three batches of QGS products were examined and no remarkable variations in terms of the five chemicals were found [119].

Stability test of proprietary products

Stability test is used to evaluate product quality over time and determine recommended shelf life. The five markers mentioned above were used as indicators to evaluate the product stability of QGS. For example, the accelerated conditional stability test was carried out with four time points in a period of three months in chambers at $40 \pm 2^\circ\text{C}$ and $75 \pm 5\%$ of humidity. The five markers were quite stable during the period; only paeonol showed a slight decrease of 5% immediately after production [119].

Diagnosis of herbal intoxication

Toxic components may be used as chemical markers in screening methods, e.g. rapid diagnosis of acute hidden aconite poisoning in urine samples by HPLC-MS [107]. Five pairs of aconite alkaloids (i.e. aconitine and benzoylaconitine, yunaconitine and deacetyl-yunaconitine, mesaconitine and benzoylmesaconitine, hypaconitine and benzoylhypaconitine, and crasscauline A and deacetyl-crasscauline A) were chosen as markers to develop a LC-MS screening method. The screening method was applied to a clinical investigation of 15 cases of suspected herbal poisoning, of which 11 cases were tested by LC-MS [107].

Lead compounds for new drug discovery

The components responsible for the therapeutic effects may be investigated as lead compounds for new drug discovery. Gambogic acid (Figure 2), one of the major caged xanthones of gamboges, is used as a chemical marker for quality control and safety evaluation of gamboges [120-123]. As its cytotoxicity is attributed to cell apoptosis induction [124-128], gambogic acid is a potential lead compound for new anti-cancer drugs [124-126] and has recently been approved by the State Food and Drug Administration of China for clinical trials of cancer treatment [129].

Problems

Chemical markers are indispensable to quality control of herbal medicines; yet many problems remain to be solved.

Shortage of chemical markers

At present, some herbs do not have markers for quality control. According to the Chinese Pharmacopoeia (2005 edition), only 281 out of 551 herbs have one or two chemical markers for quality control. A total of 282 chemical markers have been listed [3] for qualitative or quantitative analysis of herbs. Moreover, many herbal medicines share the same chemical markers for quality control (Table 2).

Table 2: Chemical markers shared by various herbal medicines in the Chinese Pharmacopoeia (2005 English version)

Chemical marker	Herb	Page no
Paeoniflorin	<i>Radix Paeoniae Alba</i>	222
	<i>Radix Paeoniae Rubra</i>	223
Chlorogenic acid	<i>Flos Lonicerae</i>	62
	<i>Folium Eucommiae</i>	70
	<i>Flos Chrysanthemi</i>	57
	<i>Folium Pyrosiae</i>	76
	<i>Flos Lonicerae Japonicae</i>	62
	<i>Herba Saussureae Involucratae</i>	151
Hyperoside	<i>Folium Crataegi</i>	69
	<i>Herba Hyperici Perforati</i>	139
Rutin	<i>Folium Mori</i>	74
	<i>Flos Sophorae</i>	65
	<i>Herba Saussureae Involucratae</i>	151
Naringin	<i>Exocarpium Citri Grandis</i>	52
	<i>Fructus Aurantii</i>	83
	<i>Rhizoma Drynariae</i>	264
Berberine	<i>Rhizoma Coptidis</i>	256
	<i>Cortex Phellodendron Amuren</i>	47
	<i>Cortex Phellodendron Chinensis</i>	48
	<i>Caulis Mahoniae</i>	26
Quercetin	<i>Herba Euphorbiae Humifusa</i>	137
	<i>Folium Apocyni Veneti</i>	67
	<i>Herba Lysimachiae</i>	143
Ferulic acid	<i>Radix Angelicae Sinensis</i>	191
	<i>Rhizoma et Radix Ligustici</i>	266
Scutellarin	<i>Herba Scutellariae Barbatae</i>	153
	<i>Herba Erigerontis</i>	135
Osthole	<i>Fructus Cnidii</i>	90
	<i>Radix Angenicae Pubescens</i>	190
Gentiopicrin	<i>Radix Gentianae Macrophyllae</i>	216
	<i>Radix et Rhizoma Gentianae</i>	204
Buddleioside	<i>Flos Buddleiae</i>	54
	<i>Flos Chrysanthemi Indici</i>	58

Unqualified purity

Inconsistency in quality is a common problem among the commercially available chemical markers. The overall quality of chemical markers may be influenced by various physical and chemical factors such as described and exemplified below.

Solvents

Gambogic acid is one of the major characteristic caged xanthones in gamboges and is therefore an ideal chemical marker for quality control. However, during the isolation and purification processes, gambogic acid can be transformed by the nucleophilic addition of methanol to the olefinic bond at C-10 when stored in methanol solution at room temperature (Figure 3) [130].

Temperature

Bioactive components of *Radix Astragali*, isoflavonoids have been used as chemical markers in the quality control of the herb [18-20]. The relative contents of flavonoids




Figure 3
Gambogic acid (**1**) and gambogoic acid (**2**) and the possible derivative schemes.

varied significantly among samples obtained with different extraction methods (Figure 4). The chemical profiles of samples with microwave assisted extraction, reflux or Soxhlet were compared. Isoflavonoid glycoside malonates were converted into their respective glycosides or flavonoid glycons (Figure 5) during the prolonged conventional extraction procedures with Soxhlet and reflux at higher temperature [18].

Light

Cinnamaldehyde is the chemical marker for the quantitative evaluation of *Cortex Cinnamomi* [131]. This compound is light-sensitive. When exposed to light at room temperature for six hours, 10% of the content of cinnamaldehyde was lost; and 36 hours later, only 25% was left (Figure 6). Later studies indicated that this compound

gradually transformed to crystallized cinnamic acid when exposed to light (Figure 7).

Epimeric mixture

Stereoisomers of some phytochemicals often co-exist in nature and are sometimes mistakenly isolated as 'pure' compounds. Most stereoisomers possess very different bioactivities from each other. Gambogic acid, a chemical marker for the gamboges [120,121], has two epimers i.e. 2(R)-gambogic acid and 2(S)-gambogic acid in nature [77,132]. The epimers have different inhibitory effects on CYP2C9 which is an important enzyme in the liver. The two epimers should be used as separate chemical markers [77]. The two epimers were eluted as a fine peak on a C₁₈ column; they can be separated on a C₈ column under optimized conditions [122,123].




Figure 4
HPLC chromatograms of *Radix Astragali* with reflux extraction (A) and with microwave assisted extraction (B). (1) Calycosin-7-O- β -D-glucoside, (2) Calycosin-7-O- β -D-glucoside-6"-O-malonate, (3) Ononin, (4) (6aR,11aR)-3-Hydroxy-9,10-dimethoxypterocarpan-3-O- β -D-glucoside, (5) (3R)-7,29-Dihydroxy-39,49-dimethoxy-isoflavan-7-O- β -D-glucoside, (6) Calycosin, (7) Formononetin-7-O- β -D-glucoside-6"-O-malonate, (8) Astrapterocarpangluicoside-6"-O-malonate, (9) Formononetin, (10) (6aR,11aR)-3-Hydroxy-9,10-dimethoxypterocarpan.

Conformations


Spectral complexity of a compound sometimes leads to confusion on its purity. Biflavonoids, for instance, always show substantial spectral complexity at the dimeric level due to hindered rotation between the flavanone and the flavanonol moieties around the C-3/C-8" axis. GB1 (3",4',4",5,5",7',7"-heptahydroxy-3,8"-biflavanone) is a major biflavonoids of *Garcinia kola* Heckel which is a plant native to Nigeria and Ghana and is often chewed by the locals for tooth cleaning. GB1 is an ideal marker for *G. kola*. The NMR spectra of GB1 obtained at 21°C exhibited two sets of signals, which appeared to be a mixture of two characteristic conformations. When measured at 70°C and 90°C, GB1 showed a single set of signals, the higher the temperature, the faster the hindered rotation between the flavanone and the flavanonol moieties around C-3/C-8" axis. When the rotation was fast enough, the compound existed at a relatively stable conformation, and the spectral complexity at the dimeric level disappeared. When measured at much lower temperatures such as -30°C and -50°C, GB1 showed the same behaviour [133]. We finally confirmed that GB1 was a pure compound [133].

Conclusion


Quality control of herbal medicines aims to ensure its quality, safety and efficacy. Chemical markers are pivotal in the current practice of quality control. Chemical markers should be used at various stages of the development and manufacturing of a herbal medicine, such as authentication and differentiation of species, collecting and harvesting, quality evaluation, stability assessment, diagnosis of intoxication and discovery of lead compounds. Lack of chemical markers remains a major problem for the quality control of herbal medicines. In many cases, we do not have sufficient chemical and pharmacological data of chemical markers. Furthermore, there are many technical challenges in the production of chemical markers. For example, temperature, light and solvents often cause degradation and/or transformation of purified components; isomers and conformations may also cause confusions of chemical markers.

Abbreviations


AAs: aristolochic acids; PAs: pyrrolizidine alkaloids; QGS: *Qingfu Guanjie Shu*; TLC: thin layer chromatography; GC-FID: gas chromatography – flame ionization detection;

**Figure 5**

Possible schemes of conversion of flavonoid glycoside malonates to their related flavonoid glycoside and flavonoid during reflux extraction of *Radix Astragali*. (1) Calycosin-7-O-β-D-glucoside, (2) Calycosin-7-O-β-D-glucoside-6"-O-malonate, (3) Ononin, (4) (6aR,11aR)-3-Hydroxy-9,10-dimethoxypterocarpan-3-O-β-D-glucoside, (5) (3R)-7,29-Dihydroxy-39,49-dimethoxy-isoflavan-7-O-β-D-glucoside, (6) Calycosin, (7) Formononetin-7-O-β-D-glucoside-6"-O-malonate, (8) Astrapterocarpanglucoside-6"-O-malonate, (9) Formononetin, (10) (6aR,11aR)-3-Hydroxy-9,10-dimethoxypterocarpan.

**Figure 6**

Determination of cinnamaldehyde samples exposed to light in different durations.

**Figure 7**

Conversion of cinnamaldehyde to cinnamic acid when exposed to light.

GC-MS: gas chromatography – mass spectrometry; HPLC-UV: high-performance liquid chromatography – ultraviolet detection; HPLC-ELSD: high-performance liquid chromatography – evaporative light scattering detection; HPLC-MS: high-performance liquid chromatography – mass spectrometry

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

SL collected references and drafted the manuscript, QH, CQ, JS and CC participated in the discussion and drafting of the manuscript, HX conceived the idea and finalized the manuscript. All authors read and approved the final version of the manuscript.

Acknowledgements

This research was funded by the Hong Kong Jockey Club Charities Trust.

References

1. World Health Organization: **Traditional medicine**. [<http://www.who.int/mediacentre/factsheets/fs134/en/>].
2. The European Medicines Agency: **Reflection paper on markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products**. [\[http://www.emea.europa.eu/pdfs/human/hmpc/25362907en.pdf\]](http://www.emea.europa.eu/pdfs/human/hmpc/25362907en.pdf).
3. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I*. Beijing: People's Medical Publishing House; 2005:8-11. A123-25.
4. Roy Upton RH: *American Herbal Pharmacopoeia* [<http://www.herbal-ahp.org/>].
5. Srinivasan VS: **Challenges and scientific issues in the standardization of botanicals and their preparations. United States Pharmacopeia's dietary supplement verification program – a public health program**. *Life Sci* 2006, **78**:2039-43.
6. Chan SSK, Li SL, Lin G: **Pitfalls of the selection of chemical markers for the quality control of medicinal herbs**. *J Food Drug Anal* 2007, **15**:365-71.
7. Li HJ, Jiang Y, Li P: **Chemistry, bioactivity and geographical diversity of steroidal alkaloids from the Liliaceae family**. *Nat Prod Rep* 2006, **23**:735-52.
8. Lin BQ, Ji H, Li P, Fang W, Jiang Y: **Inhibitors of acetylcholine esterase in vitro – screening of steroidal alkaloids from *Fritillaria* species**. *Planta Med* 2006, **72**:814-8.
9. Lin BQ, Ji H, Li P, Jiang Y, Fang W: **Selective antagonism activity of alkaloids from Bulbs *Fritillariae* at muscarinic receptors: functional studies**. *Eur J Pharmacol* 2006, **551**:125-30.
10. Lin G, Li P, Li SL, Chan SW: **Chromatographic analysis of *Fritillaria* isosteroidal alkaloids, the active ingredients of Beimu, the antitussive traditional Chinese medicinal herb**. *J Chromatogr A* 2001, **935**:321-38.
11. Lee S: **Artemisinin, promising lead natural product for various drug developments**. *Mini Rev Med Chem* 2007, **7**:411-22.
12. China Collaborative Research Group: **Antimalaria studies on Qinghaosu**. *Chin Med J (Engl)* 1979, **92**:811-6.
13. Dhingra V, Rao KV, Narasimhan ML: **Current status of artemisinin and its derivatives as antimalaria drugs**. *Life Sci* 2000, **66**:279-300.

14. Liu CZ, Zhou HY, Zhao Y: **An effective method for fast determination of artemisinin in *Artemisia annua* L. by high performance liquid chromatography with evaporative light scattering detection.** *Anal Chim Acta* 2007, **581**:298-302.
15. Ma C, Wang H, Lu X, Xu G, Liu B: **Metabolic fingerprinting investigation of *Artemisia annua* L. in different stages of development by gas chromatography and gas chromatography-mass spectrometry.** *J Chromatogr A* 2008, **1186**:412-419.
16. Lommen WJ, Elzinga S, Verstappen FW, Bouwmeester HJ: **Artemisinin and sesquiterpene precursors in dead and green leaves of *Artemisia annua* L. crops.** *Planta Med* 2007, **73**:1133-9.
17. Zhen HZ, Dong ZH, She Q: **Modern study of traditional Chinese medicine Volume 4.** Beijing: Xueyuan Publications; 1998:3883-942.
18. Song JZ, Mo SF, Yip YK, Qiao CF, Han QB, Xu HX: **Development of microwave assisted extraction for the simultaneous determination of isoflavonoids and saponins in *Radix Astragalii* by high performance liquid chromatography.** *J Sep Sci* 2007, **30**:819-24.
19. Yu QT, Qi LW, Li P, Yi L, Zhao J, Bi Z: **Determination of seventeen main flavonoids and saponins in the medicinal plant Huang-qi (*Radix Astragali*) by HPLC-DAD-ELSD.** *J Sep Sci* 2007, **30**:1292-9.
20. Zhang X, Xiao HB, Xue XY, Sun YG, Liang XM: **Simultaneous characterization of isoflavonoids and astragalosides in two *Astragalus* species by high-performance liquid chromatography coupled with atmospheric pressure chemical ionization tandem mass spectrometry.** *J Sep Sci* 2007, **30**:2059-69.
21. Sarris J: **Herbal medicines in the treatment of psychiatric disorders: a systematic review.** *Phytother Res* 2007, **21**:703-16.
22. Butterweck V: **Mechanism of action of St John's wort in depression: what is known?** *CNS Drugs* 2003, **17**:539-62.
23. Butterweck V, Schmidt M: **St. John's wort: role of active compounds for its mechanism of action and efficacy.** *Wien Med Wochenschr* 2007, **157**:356-61.
24. Noldner M, Schotz K: **Rutin is essential for the antidepressant activity of *Hypericum perforatum* extracts in the forced swimming test.** *Planta Med* 2002, **68**:577-80.
25. Liu F, Pan C, Drumm P, Ang CY: **Liquid chromatography-mass spectrometry studies of St. John's wort methanol extraction: active constituents and their transformation.** *J Pharm Biomed Anal* 2005, **37**:303-12.
26. Shah AK, Avery BA, Wyandt CM: **Content analysis and stability evaluation of selected commercial preparations of St. John's wort.** *Drug Dev Ind Pharm* 2005, **31**:907-16.
27. Chandrasekera DH, Welham KJ, Ashton D, Middleton R, Heinrich M: **Quantitative analysis of the major constituents of St John's wort with HPLC-ESI-MS.** *J Pharm Pharmacol* 2005, **57**:1645-52.
28. Smelcerovic A, Spiteller M, Zuehlke S: **Comparison of methods for the exhaustive extraction of hypericins, flavonoids and hyperforin from *Hypericum perforatum* L.** *J Agric Food Chem* 2006, **54**:2750-3.
29. Rückert U, Likussar W, Michelitsch A: **Simultaneous determination of total hypericin and hyperforin in St. John's wort extracts by HPLC with electrochemical detection.** *Phytochem Anal* 2007, **18**:204-8.
30. ADIS R&D PROFILE: **EGb 761: Ginkgo biloba extract, Ginkor.** *Drugs in R & D* 2003, **4**:188-93.
31. Van Beek TA: **Chemical analysis of *Ginkgo biloba* leaves and extracts.** *J Chromatogr A* 2002, **967**:21-55.
32. Ding S, Dudley E, Plummer S, Tang J, Newton RP, Brenton AG: **Quantitative determination of major active components in *Ginkgo biloba* dietary supplements by liquid chromatography/mass spectrometry.** *Rapid Commun Mass Spectrom* 2006, **20**:2753-60.
33. Croom E, Pace R, Paletti A, Sardone N, Gray DE: **Single-laboratory validation for the determination of terpene lactones in *Ginkgo biloba* dietary supplement crude materials and finished products by high-performance liquid chromatography with evaporative light-scattering detection.** *J AOAC Int* 2007, **90**:647-58.
34. Gray DE, Messer D, Porter A, Hefner B, Logan D, Harris RK, Clark AP, Algaier JA, Overstreet JD, Smith CS: **Analysis of flavonol aglycones and terpene lactones in *Ginkgo biloba* extract: A comparison of high-performance thin-layer chromatography and column high-performance liquid chromatography.** *J AOAC Int* 2007, **90**:1203-9.
35. Bent S, Padula A, Moore D, Patterson M, Mehling W: **Valerian for sleep: a systematic review and meta-analysis.** *Am J Med* 2006, **119**:1005-12.
36. Taibi DM, Landis CA, Petry H, Vitiello MV: **A systematic review of valerian as a sleep aid: safe but not effective.** *Sleep Med Rev* 2007, **11**:209-30.
37. Shohet D, Wills RB, Stuart DL: **Valepotriates and valerenic acids in commercial preparations of valerian available in Australia.** *Pharmazie* 2001, **56**:860-3.
38. Torrado JJ: **In vitro release of valerenic and hydroxyvalerenic acids from valerian tablets.** *Pharmazie* 2003, **58**:636-8.
39. Goppel M, Franz G: **Stability control of valerian ground material and extracts: a new HPLC method for the routine quantification of valerenic acids and lignans.** *Pharmazie* 2004, **59**:446-52.
40. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I.* Beijing: People's Medical Publishing House; 2005:205-206, 209, 223.
41. Guan J, Lai CM, Li SP: **A rapid method for the simultaneous determination of 11 saponins in *Panax notoginseng* using ultra performance liquid chromatography.** *J Pharm Biomed Anal* 2007, **44**:996-1000.
42. Kim SN, Ha YY, Shin H, Son SH, Wu SJ, Kim YS: **Simultaneous quantification of 14 ginsenosides in *Panax ginseng* C.A. Meyer (Korean red ginseng) by HPLC-ELSD and its application to quality control.** *J Pharm Biomed Anal* 2007, **45**:164-70.
43. Wan JB, Li SP, Chen JM, Wang YT: **Chemical characteristics of three medicinal plants of the *Panax* genus determined by HPLC-ELSD.** *J Sep Sci* 2007, **30**:825-32.
44. Chan TWD, But PPH, Cheng SW, Kwok IMY, Lan FW, Xu HX: **Differentiation and authentication of *Panax ginseng*, *Panax quinquefolius*, and ginseng products by using HPLC/MS.** *Anal Chem* 2000, **72**:1281-7.
45. Wang XM, Sakuma T, Asafu-adjei E, Shiu GK: **Determination of ginsenosides in plant extracts from *Panax ginseng* and *Panax quinquefolius* by LC/MS/MS.** *Anal Chem* 1999, **71**:1579-84.
46. Wang CZ, Aung HH, Ni M, Wu JA, Tong R, Wicks S, He TC, Yuan CS: **Red American ginseng: ginsenoside constituents and antiproliferative activities of heat-processed *Panax quinquefolius* roots.** *Planta Med* 2007, **73**:669-74.
47. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I.* Beijing: People's Medical Publishing House; 2005:134.
48. Pei LK, Guo BL: **A review on research of raw material and cut crude drug of Herba Epimedii in last ten years (Chinese).** *Zhongguo Zhongyao Zazhi* 2007, **32**:466-71.
49. Zhang G, Qin L, Shi Y: **Epimedium-derived phytoestrogen flavonoids exert beneficial effect on preventing bone loss in late postmenopausal women: a 24-month randomized, double-blind and placebo-controlled trial.** *J Bone Miner Res* 2007, **22**:1072-9.
50. Chen XJ, Guo BL, Li SP, Zhang QW, Tu PF, Wang YT: **Simultaneous determination of 15 flavonoids in *Epimedium* using pressurized liquid extraction and high-performance liquid chromatography.** *J Chromatogr A* 2007, **1163**:96-104.
51. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I.* Beijing: People's Medical Publishing House; 2005:107.
52. Qiao CF, Han QB, Mo SF, Song JZ, Xu LJ, Chen SL, Yang DJ, Kong LD, Kung HF, Xu HX: **Psoralenoside and isopsoralenoside, two new benzofuran glycosides from *Psoralea corylifolia*.** *Chem Pharm Bull* 2006, **54**:714-6.
53. Qiao CF, Han QB, Song JZ, Mo SF, Kong LD, Kung HF, Xu HX: **Quality assessment of *Fructus Psoraleae*.** *Chem Pharm Bull* 2006, **54**:887-90.
54. Cosyns JP: **Aristolochic acid and 'Chinese herbs nephropathy': a review of the evidence to date.** *Drug Safety* 2003, **26**:33-48.
55. Fu PP, Xia QS, Lin G, Chou MW: **Pyrrolizidine alkaloids – genotoxicity, metabolism enzymes, metabolic action, and mechanisms.** *Drug Metab Rev* 2004, **36**:1-55.
56. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I.* Beijing: People's Medical Publishing House; 2005:XXI.
57. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I.* Beijing: People's Medical Publishing House; 2005:201.

58. Chan W, Lee KC, Liu N, Cai Z: **A sensitivity enhanced high-performance liquid chromatography fluorescence method for the detection of nephrotoxic and carcinogenic aristolochic acid in herbal medicines.** *J Chromatogr A* 2007, **1164**:113-9.
59. Yuan J, Liu Q, Wei G, Tang F, Ding L, Yao S: **Characterization and determination of six aristolochic acids and three aristolactams in medicinal plants and their preparations by high-performance liquid chromatography-photodiode array detection/electrospray ionization massspectrometry.** *Rapid Commun Mass Spectrom* 2007, **21**:2332-42.
60. Sorenson WVR, Sullivan D: **Determination of aristolochic acid I in botanicals and dietary supplements potentially contaminated with aristolochic acid I using LC-UV with confirmation by LC/MS: collaborative study.** *J AOAC Int* 2007, **90**:925-33.
61. Shi S, Li W, Liao Y, Cai Z, Liu H: **Online concentration of aristolochic acid I and II in Chinese medicine preparations by micellar electrokinetic chromatography.** *J Chromatogr A* 2007, **1167**:120-4.
62. Röder E: **Medicinal plants in China containing pyrrolizidine alkaloids.** *Pharmazie* 2000, **55**:71-23.
63. World Health Organization: *Health and Safety Guide No.26: Pyrrolizidine alkaloids health and safety guide* 1989:1-17.
64. Darmananda S: **Safety issue affecting herbs: pyrrolizidine alkaloids.** [http://www.itmonline.org/arts/pas.htm].
65. Medicines and Healthcare Products Regulatory Agency: **Public consultation: Proposals to prohibit the sale, supply or importation of unlicensed medicinal products for internal use which contain Senecio species and proposals to amend three existing orders.** [http://www.mhra.gov.uk/home/idcplg?IdService=GET_FILE&dDocName=CON2030749&RevisionSelection-Method=LatestReleased].
66. Colegate SM, Edgar JA, Knill AM, Lee ST: **Solid-phase extraction and HPLC-MS profiling of pyrrolizidine alkaloids and their N-oxides: a case study of *Echium plantagineum*.** *Phytochem Anal* 2005, **16**:108-19.
67. Yu L, Xu Y, Feng H, Li SF: **Separation and determination of toxic pyrrolizidine alkaloids in traditional Chinese herbal medicines by micellar electrokinetic chromatography with organic modifier.** *Electrophoresis* 2005, **26**:3397-404.
68. Chou MW, Fu PP: **Formation of DHP-derived DNA adducts in vivo from dietary supplements and Chinese herbal plant extracts containing carcinogenic pyrrolizidine alkaloids.** *Toxicol Ind Health* 2006, **22**:321-7.
69. Ndjoko K, Wolfender JL, Röder E, Hostettmann K: **Determination of pyrrolizidine alkaloids in senecio species by liquid chromatography/thermospray-mass spectrometry and liquid chromatography/nuclear magnetic resonance spectroscopy.** *Planta Med* 1999, **65**:562-6.
70. Zhang F, Wang CH, Xiong AZ, Wang W, Yang L, Branford-White CJ, Wang ZT, Bligh SW: **Quantitative analysis of total retronecine esters-type pyrrolizidine alkaloids in plant by high performance liquid chromatography.** *Anal Chim Acta* 2007, **605**:94-101.
71. Zhang F, Wang CH, Wang W, Chen LX, Ma HY, Zhang CF, Zhang M, Bligh SW, Wang ZT: **Quantitative analysis by HPLC-MS² of the pyrrolizidine alkaloid adonifoline in *Senecio scandens*.** *Phytochem Anal* 2007, **19**(1):25-31.
72. Li SL, Lin G, Fu PP, Chan CL, Li M, Jiang ZH, Zhao ZZ: **Identification of five hepatotoxic pyrrolizidine alkaloids in a commonly used traditional Chinese medicinal herb, *Herba Senecionis Scandentis* (Qianliguang).** *Rapid Commun Mass spectrom* 2008, **22**(4):598-602.
73. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I*. Beijing: People's Medical Publishing House; 2005:197.
74. Qiao CF, He ZD, Han QB, Xu HX, Jiang RW, Li SL, Zhang YB, But PPH, Shaw PC: **The use of lobetyolin and HPLC-UV fingerprints for quality assessment of Radix Codonopsis.** *J Food Drug Anal* 2007, **15**:258-64.
75. Jiangsu New Medical College: *Dictionary of Chinese Traditional Medicines*. Shanghai: Shanghai Scientific and Technical Publishers; 1977:3805-07.
76. Panthong A, Norkaew P, Kanjanapothi D, Taesotikul T, Anantachoke N, Reutrakul V: **Anti-inflammatory, analgesic and antipyretic activities of the extract of gamboge from *Garcinia hanburyi* Hook f.** *J Ethnopharmacol* 2007, **111**:335-40.
77. Han Q, Yang L, Liu Y, Wang Y, Qiao C, Song J, Xu L, Yang D, Chen S, Xu H: **Gambogic acid and epigambogic acid, C-2 epimers with novel anticancer effects from *Garcinia hanburyi*.** *Planta Med* 2006, **72**:281-4.
78. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I*. Beijing: People's Medical Publishing House; 2005:239.
79. Greger H: **Structural relationships, distribution and biological activities of stemona alkaloids.** *Planta Med* 2006, **72**:99-113.
80. Pilli RA, Rosso GB, De Oliveira Mda C: **The Stemona alkaloids.** *Alkaloids Chem* 2005, **62**:77-173.
81. Pilli RA, Ferreira de Oliveira MC: **Recent progress in the chemistry of the Stemona alkaloids.** *Nat Prod Rep* 2000, **17**:117-27.
82. Xu YT, Hon PM, Jiang RW, Cheng L, Li SH, Chan YP, Xu HX, Shaw PC, But PP: **Antitussive effects of *Stemona tuberosa* with different chemical profiles.** *J Ethnopharmacol* 2006, **108**:46-53.
83. Chung HS, Hon PM, Lin G, But PP, Dong H: **Antitussive activity of Stemona alkaloids from *Stemona tuberosa*.** *Planta Med* 2003, **69**:914-20.
84. Li SL, Jiang RW, Hon PM, Cheng L, Xu HX, Greger H, But PP, Shaw PC: **Quality evaluation of *Radix Stemona* through simultaneous quantification of bioactive alkaloids by high-performance liquid chromatography coupled with diode array and evaporative light scattering detectors.** *Biomed Chromatogr* 2007, **21**:1088-94.
85. Zhou Y, Jiang RW, Hon PM, Xu YT, Chan YM, Chan TW, Xu HX, Ding LS, But PP, Shaw PC: **Analyses of Stemona alkaloids in *Stemona tuberosa* by liquid chromatography/tandem mass spectrometry.** *Rapid Commun Mass Spectrom* 2006, **20**:1030-8.
86. Wang PS, Gao YX, Wang YX, Yoshiyasu F, Iwao M, Michiharu S: **Phthalides from the rhizome of *Ligusticum wallichii*.** *Phytochemistry* 1984, **23**:2033-8.
87. Wang PS: **Survey of investigation on chemical principles and biological activities of *Ligusticum wallichii* (Chinese).** *Zhongguo Yi Yao Gongye* 1988, **19**:553-9.
88. Kobayashi M, Fujita M, Mitsuhashi H: **Studies on the constituents of Umbelliferae plants. XV. Constituents of *Cnidium officinale*: Occurrence of pregnenolone, coniferylf erulate and hydroxyphthalides.** *Chem Pharm Bull* 1987, **35**:1427-33.
89. Tsuchida T, Kobayashi M, Kaneko K, Mitsuhashi H: **Studies on the constituents of Umbelliferae plants. XVI. Isolation and structures of three new ligustilide derivatives from *Angelica acutiloba*.** *Chem Pharm Bull* 1987, **35**:4460-4.
90. Kobayashi M, Mitsuhashi H: **Studies on the constituents of Umbelliferae plants XVII: Structures of three new ligustilide derivatives from *Ligusticum wallichii*.** *Chem Pharm Bull* 1987, **35**:4789-92.
91. Kaoudaji M, Pachtere F, Pouget C, Chulia AJ: **Three additional phthalide derivatives, an epoxymonomer and two dimers, from *Ligusticum wallichii* rhizomes.** *J Nat Prod* 1986, **49**:872-7.
92. Naito T, Katsuhara T, Niitsu K, Ikeya Y, Okada M, Mitsuhashi H: **Phthalide dimers from *Ligusticum chuanxiong* Hort.** *Heterocycles* 1991, **32**:2433-42.
93. Naito T, Kubota K, Shimoda Y, Sato T, Ikeya Y, Okada M: **Effects of constituents in a Chinese crude drug, *Ligustici Chuanxiong Rhizoma* on vasoconstrictor and blood viscosity.** *Nat Med* 1995, **49**:288-92.
94. Kobayashi S, Mimura Y, Notoya K, Kimura I, Kimura M: **Antiproliferative effects of the traditional Chinese medicine Shimotsu-To, its component *Cnidium Rhizome* and derived compounds on primary cultures of mouse aorta smooth muscle cells.** *Jap J Pharmacol* 1992, **60**:397-401.
95. Kobayashi S, Mimura Y, Naito Y, Kimura I, Kimura M: **Chemical structure-activity of *Cnidium Rhizome* – derived phthalides for the competence inhibition of proliferation in primary cultures of mouse aorta smooth muscle cells.** *Jap J Pharmacol* 1993, **63**:353-9.
96. Foye WO, Wang HP, Wang HF: **Synthesis and platelet aggregation inhibitory effects of Harman and phthalide derivatives related to *Ligusticum chuanxiong* Hort. constituents.** *Med Chem Res* 1997, **7**:180-91.
97. Lee TF, Lin YL, Huang YT: **Studies on antiproliferative effects of phthalides from *Ligusticum chuanxiong* in hepatic stellate cells.** *Planta Med* 2007, **73**:527-34.
98. Chan SS, Cheng TY, Lin G: **Relaxation effects of ligustilide and senkyunolide A, two main constituents of *Ligusticum chuanxiong*, in rat isolated aorta.** *J Ethnopharmacol* 2007, **111**:677-80.

99. Chan SS, Choi AO, Jones RL, Lin G: **Mechanisms underlying the vasorelaxing effects of butylidenephthalide, an active constituent of *Ligusticum chuanxiong*, in rat isolated aorta.** *Eur J Pharmacol* 2006, **537**:111-7.
100. Li SL, Lin G, Tam YK: **Time-course accumulation of main bioactive components in the rhizome of *Ligusticum chuanxiong*.** *Planta Med* 2006, **72**:278-80.
101. Jiang RW, Hon PM, But PPH, Chung HS, Lin G, Ye WC, Mak TCW: **Isolation and stereochemistry of two new alkaloids from *Stemona tuberosa*.** *Tetrahedron* 2002, **58**:6705-12.
102. Jiang RW, Hon PM, Zhou Y, Chan YM, Xu YT, Xu HX, Greger H, Shaw PC, But PPH: **Alkaloids and chemical diversity of *Stemona tuberosa*.** *J Nat Prod* 2006, **69**:749-54.
103. Jiang RW, Hon PM, Xu YT, Chan YM, Xu HX, Shaw PC, But PPH: **Isolation and chemotaxonomic significance of tuberostemos-pironine-type alkaloids from *Stemona tuberosa*.** *Phytochemistry* 2006, **67**:52-57.
104. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I*. Beijing: People's Medical Publishing House; 2005:185.
105. Fujita Y, Terui K, Fujita M, Kakizaki A, Sato N, Oikawa K, Aoki H, Takahashi K, Endo S: **Five cases of aconite poisoning: toxicokinetics of aconitines.** *J Anal Toxicol* 2007, **31**:132-7.
106. Poon WT, Lai CK, Ching CK, Tse KY, So YC, Chan YC, Hau LM, Mak TW, Chan AY: **Aconite poisoning in camouflage.** *Hong Kong Med J* 2006, **12**:456-9.
107. Lai CK, Poon WT, Chan YW: **Hidden aconite poisoning: identification of yunnaconitine and related *Aconitum* alkaloids in urine by liquid chromatography-tandem mass spectrometry.** *J Anal Toxicol* 2006, **30**:426-33.
108. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I*. Beijing: People's Medical Publishing House; 2005:188.
109. Ohta H, Seto Y, Tsunoda N, Takahashi Y, Matsuura K, Ogasawara K: **Determination of *Aconitum* alkaloids in blood and urine samples II. Capillary liquid chromatographic-frit fast atom bombardment mass spectrometric analysis.** *J Chromatogr B* 1998, **714**:215-21.
110. Gutser UT, Friese J, Heubach JF, Matthiesen T, Selva N, Wilfert B, Gleitz J: **Mode of antinociceptive and toxic action of alkaloids of *Aconitum* spec.** *Naunyn Schmiedebergs Arch Pharmacol* 1998, **357**:39-48.
111. Xie Y, Jiang ZH, Zhou H, Xu HX, Liu L: **Simultaneous determination of six *Aconitum* alkaloids in proprietary Chinese medicines by high-performance liquid chromatography.** *J Chromatogr A* 2005, **1093**:195-203.
112. Song JZ, Mo SF, Yip YK, Qiao CF, Han QB, Xu HX: **Chemical comparison and classification of cultivated *Radix Astragali* in different region of China by determination of isoflavonoids and astragalosides in its bark and xylem with principal component analysis.** *J Pharm Biomed Anal* 2008, **47**:399-406.
113. Cai X, Zhou H, Wong YF, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L: **Suppressive effects of QFGJS, a preparation from an anti-arthritis herbal formula, on rat experimental adjuvant-induced arthritis.** *Bioch Biophy Res Commun* 2005, **337**:586-94.
114. Zhou H, Wong YF, Cai X, Liu ZQ, Jiang ZH, Bian ZX, Xu HX, Liu L: **Suppressive effects of JCICM-6, the extracts of an anti-arthritis herbal formula, on the experimental inflammatory and nociceptive models in rodents.** *Biol Pharm Bull* 2006, **29**:253-60.
115. Liu L, Buchner E, Beitz D, Schmidt-Weber CB, Kaever V, Emmrich F, Kinne RW: **Amelioration of rat experimental arthritides by treatment with the alkaloid sinomenine.** *Int J Immunopharmacol* 1996, **18**:529-43.
116. Liang J, Zhou A, Chen M, Xu S: **Negatively regulatory effects of paeoniflorin on immune cells.** *Eur J Pharmacol* 1990, **183**:901-02.
117. Rafatullah S, Tariq M, Al-Yahya MA, Mossa JS, Ageel AM: **Evaluation of turmeric (*Curcuma longa*) for gastric and duodenal antiulcer activity in rats.** *J Ethnopharmacol* 1990, **29**:25-34.
118. Hikino H, Konno C, Takata H, Yamada Y, Yamada C, Ohizumi Y, Sugio K, Fujimura H: **Antiinflammatory principles of *Aconitum* roots.** *J Pharmacobiodyn* 1980, **3**:514-25.
119. Xie Y, Jiang ZH, Zhou H, Cai X, Wong YF, Liu ZQ, Bian ZX, Xu HX, Liu L: **Combinative method using HPLC quantitative and qualitative analyses for quality consistency assessment of a herbal medicinal preparation.** *J Pharm Biomed Anal* 2007, **43**:204-12.
120. Liu WY, Feng F, You QD, Zhang ZX: **Determination of gambogic acid in gamboge by RP-HPLC (Chinese).** *Zhongcaoyao* 2003, **34**:706-07.
121. Yang H, Cong XD, Jiang WL, Liu LX: **Determination of the content of gambogic acid and its derivatives in gamboge by HPLC-ELSD.** *J Chin Pharm Univ* 1999, **30**:202-05.
122. Song JZ, Yip YK, Han QB, Qiao CF, Xu HX: **Rapid determination of polyprenylated xanthones in gamboge resin of *Garcinia hanburyi* by HPLC.** *J Sep Sci* 2007, **30**:304-09.
123. Li SL, Song JZ, Han QB, Qiao CF, Xu HX: **Improved high performance liquid chromatographic method for simultaneous determination of 12 cytotoxic caged xanthones in gamboge, a potential anticancer resin from *Garcinia hanburyi*.** *Biomed Chromatogr* 2008, **22**:637-644.
124. Guo QL, You QD, Wu ZQ, Yuan ST, Zhao L: **General gambogic acids inhibited growth of human hepatoma SMMC-7721 cells in vitro and in nude mice.** *Acta Pharmacol Sin* 2004, **25**:769-74.
125. Yang Y, Yang L, You QD, Nie FF, Gu HY, Zhao L, Wang XT, Guo QL: **Differential apoptotic induction of gambogic acid, a novel anticancer natural product, on hepatoma cells and normal hepatocytes.** *Cancer Lett* 2007, **256**:259-66.
126. Yu J, Guo QL, You QD, Lin SS, Li Z, Gu HY, Zhang HW, Tan Z, Wang X: **Repression of telomerase reverse transcriptase mRNA and hTERT promoter by gambogic acid in human gastric carcinoma cells.** *Cancer Chemother Pharmacol* 2006, **58**:434-43.
127. Kasibhatla S, Jessen KA, Malaria Chouk S, Wang JY, English NM, Drewe J, Qiu L, Archer SP, Ponce AE, Sirisoma N, Jiang S, Zhang HZ, Gehlsen KR, Cai SX, Green DR, Tseng B: **A role for transferrin receptor in triggering apoptosis when targeted with gambogic acid.** *Proc Natl Acad Sci USA* 2005, **102**:12095-100.
128. Pandey MK, Sung B, Ahn KS, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB: **Gambogic acid, a novel ligand for transferrin receptor, potentiates TNF-induced apoptosis through modulation of the nuclear factor- $\{\kappa\}$ B signaling pathway.** *Blood* 2007, **110**:3517-25.
129. Zhou ZT, Wang JW: **Phase I human tolerability trial of gambogic acid (Chinese).** *Chin J New Drugs* 2007, **16**:79-82.
130. Han QB, Cheung S, Tai J, Qiao CF, Song JZ, Xu HX: **Stability and cytotoxicity of gambogic acid and its derivative, gambogeic acid.** *Bio Pharm Bull* 2005, **28**:2335-7.
131. Chinese Pharmacopoeia Commission: *Pharmacopoeia of the People's Republic of China Volume I*. Beijing: People's Medical Publishing House; 2005:41.
132. Han QB, Song JZ, Qiao CF, Wong L, Xu HX: **Preparative separation of gambogic acid and its C-2 epimer using recycling high-speed counter-current chromatography.** *J Chromatogr A* 2006, **1127**:298-301.
133. Han QB, Lee SF, Qiao CF, He ZD, Song JZ, Sun HD, Xu HX: **Complete NMR assignments of the antibacterial biflavanoid GBI from *Garcinia kola*.** *Chem Pharm Bull* 2005, **53**:1034-6.

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp

